Highest-materiality recent filing
All 11 director nominees elected with >1.46B votes for each.
Bristol Myers Q1 revenue $11.5B (+3%); reaffirms 2026 guidance trending upper end
Q1 revenue $11.5B, up 3% YoY (1% ex-FX); Growth Portfolio revenue $6.2B (+12% / +9% ex-FX).
Q4 revenue $12.5B (+1% YoY); Growth Portfolio rev $7.4B (+16%). Full-year rev $48.2B.
Christopher Boerner, Board Chair & CEO, presented at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.
BMY completes early settlement of ~$7.5B tender offers for 15 note series
Amended Pool 1 max purchase price to ~$3.99B; Pool 2 max to ~$3.51B.
BMY subsidiary issues €5B notes (2.973%-4.581%) to fund tender offer and general purposes
Issued €5B across five tranches: €750M (2030, 2.973%), €1.15B (2033, 3.363%), €1.15B (2038, 3.857%), €750M (2045, 4.289%), €1.2B (2055, 4.581%).
Bristol-Myers Squibb launches $7B cash tender offer for 15 series of outstanding notes
Offers up to $4B for Pool 1 notes (2026-2029 maturities) and $3B for Pool 2 notes (2031-2097).
Bristol Myers Q3 revenue $12.2B (+3% YoY), GAAP EPS $1.08, raises FY revenue guidance to ~$47.5-48B
Total revenues $12,222M (+3% YoY; +2% ex-FX); Growth Portfolio $6.9B (+18% ex-FX).
BMY Q2 revenue $12.3B, GAAP EPS $0.64, non-GAAP EPS $1.46; raises revenue guidance
Revenue $12.3B, +1% YoY; Growth Portfolio $6.6B, +18% YoY (+17% ex-FX).
Bristol Myers Squibb appoints Cristian Massacesi as CMO; Samit Hirawat departs by Nov 1
Cristian Massacesi, M.D., named EVP, Chief Medical Officer and Head of Development, effective August 1, 2025.
BMY shareholders elect all 11 directors, approve compensation, at 2025 annual meeting
All 11 director nominees elected; votes 'for' ranged from 1.49B to 1.53B.
Bristol-Myers Squibb Q1 revenue $11.2B (-6% YoY), GAAP EPS $1.20, raises FY guidance
Total revenues $11.2B, down 6% (4% ex-FX) from $11.865B in Q1 2024.
Bristol-Myers General Counsel Sandra Leung to retire in 2025
Sandra Leung notified company of her retirement from EVP, General Counsel role, effective in 2025.
BMY Q4 rev +8% to $12.3B, GAAP EPS $0.04; expands cost-savings by $2B
Q4 2024 revenues $12.3B (+8% YoY, +9% ex-FX); GAAP EPS $0.04, Non-GAAP EPS $1.67.
Bristol-Myers Squibb posts investor presentation at J.P. Morgan Healthcare Conference
Presentation posted on Jan 13, 2025, by CEO Christopher Boerner at the 43rd Annual J.P. Morgan Healthcare Conference.
Bristol Myers Q3 2024 revenue $11.9B (+8% YoY); raises full-year guidance, Cobenfy approved
Q3 2024 revenues $11.9B, up 8% (+10% ex-FX); GAAP EPS $0.60, Non-GAAP EPS $1.80.
Bristol Myers Q2 rev $12.2B (+9%), non-GAAP EPS $2.07, raises FY guidance
Revenues $12.2B up 9% YoY (+11% ex-FX); Growth Portfolio $5.6B up 18% (+21% ex-FX).
Bristol Myers Squibb elects former Agilent CEO Michael McMullen to board
Michael R. McMullen elected to board, effective July 1, 2024; board size increases to 11.
Amendment to eliminate/limit monetary liability for breach of duty of care for specified executive officers approved by majority of outstanding shares.
Bristol-Myers Squibb Q1 revenue up 5% to $11.9B; GAAP loss per share $5.89 on acquired IPRD charges
Q1 revenues $11,865M (+5% reported, +6% ex-FX); growth portfolio revenues $4,767M (+8%, +11% ex-FX).
On February 14 , 2025, Sandra Leung notified Bristol-Myers Squibb Company (the “Company”) of her intention to retire from her position as Executive Vice President, General Counsel in 2025.
On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024.
Max materiality 0.85 · Median 0.65 · Most common event earnings